Ganga Pharmaceuticals (BOM:539680) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ganga Pharmaceuticals EBITDA Margin % Related Terms
Ganga Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ganga Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ganga Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ganga Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ganga Pharmaceuticals (BOM:539680) has a EBITDA Margin % of 39.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ganga Pharmaceuticals and its competitors. This is 164% above median its historical median of 15.07. Over the past decade, Ganga Pharmaceuticals' EBITDA Margin % has ranged from 10.73 to 41.82.
Is Ganga Pharmaceuticals' EBITDA Margin % too high?
Ganga Pharmaceuticals' current EBITDA Margin % of 39.72% is 164% above median its 10-year median of 15.07. Over the past 10 years, this metric has ranged from a low of 10.73 to a high of 41.82. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Ganga Pharmaceuticals' value of 39.72% is 218.5% above this industry median. Overall, Ganga Pharmaceuticals has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ganga Pharmaceuticals' EBITDA Margin % compare to ZTS?
Ganga Pharmaceuticals' EBITDA Margin % of 39.72% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.47. Ganga Pharmaceuticals' value of 39.72% is 218.5% above this benchmark. Historically, Ganga Pharmaceuticals' own EBITDA Margin % has ranged from 10.73 to 41.82 over the past decade. While the company's 10-year median is 15.07 vs. the industry median of 12.47, Ganga Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ganga Pharmaceuticals's current EBITDA Margin % of 39.72% is 218.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ganga Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ganga Pharmaceuticals's current EBITDA Margin % is 39.72%, which is 164% above median its own 10-year median of 15.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ganga Pharmaceuticals stock overvalued right now?
Ganga Pharmaceuticals (BOM:539680) has a current EBITDA Margin % of 39.72%. The stock's GF Value™ is ₹11.85, compared to a current price of ₹12.00 — trading 1.3% above its estimated fair value. The current EBITDA Margin % is 39.72%, which is 164% above median its 10-year median of 15.07 and 218.5% above the Drug Manufacturers industry median of 12.47. Ganga Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ganga Pharmaceuticals (BOM:539680), the current EBITDA Margin % is 39.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ganga Pharmaceuticals (BOM:539680) Overvalued in 2026?
Based on GuruFocus' analysis, Ganga Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹12.00 is trading 1.3% above its estimated GF Value™ of ₹11.85.
Key valuation signals for BOM:539680:
EBITDA Margin %: 39.72% (164% above median its 10-year median of 15.07)
GF Value™: ₹11.85 vs. price of ₹12.00 (1.3% above fair value)
Industry Position: 218.5% above the Drug Manufacturers median
No single metric tells the full story. See the BOM:539680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.
62GF Score
Get the complete analysis for BOM:539680
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539680 has been successfully added to your 
